Effect of Mepolizumab in OCS Dependent Severe Eosinophilic Asthma Patients with History of Omalizumab Treatment

被引：0
|
作者：
Prazma, Charlene M. [1 ]
Magnan, Antoine [2 ]
Price, Robert [3 ]
Ortega, Hector [1 ]
Yancey, Steven W. [1 ]
Albers, Frank C. [1 ]
机构：
[1] GlaxoSmithKline, Res Triangle Pk, NC USA
[2] Univ Nantes, Nantes, France
[3] GlaxoSmithKline, Stockley Pk, England
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2015年 / 135卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2014.12.1879
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
L6
引用
收藏
页码：AB383 / AB383
页数：1
相关论文
共 50 条
  • [31] Phenotypic characterization of severe OCS-dependent atopic asthma patients treated with mepolizumab
    Prazma, C. M.
    Idzko, M.
    Bourdin, A.
    Douglass, J. A.
    Price, R. C.
    Albers, F.
    Yancey, S. W.
    ALLERGY, 2017, 72 : 326 - 326
  • [32] A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
    Davison, John
    Doe, Simon
    RESPIRATORY MEDICINE CASE REPORTS, 2021, 34
  • [33] Asthma Control In Patients With Severe Eosinophilic Asthma Treated With Mepolizumab
    Llanos-Ackert, J. -P.
    Price, R. G.
    Forshag, M.
    Yancey, S.
    Liu, M. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [34] Characterisation of an OCS-dependent severe asthma population treated with mepolizumab
    Prazma, C. M.
    Wenzel, S.
    Barnes, N.
    Douglass, J. A.
    Hartley, B. F.
    Ortega, H.
    THORAX, 2014, 69 (12) : 1141 - 1142
  • [35] Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Treatment effect by nasal polyps, aspirin/NSAID intolerance, and GERD
    Albers, F. C.
    Liu, M. C.
    Chipps, B. E.
    Chapman, K. R.
    Munoz, X.
    Bergna, M. A.
    Devouassoux, G.
    Price, R. G.
    Galkin, D., V
    ALLERGY, 2019, 74 : 363 - 363
  • [36] Treatment Response Of Mepolizumab On Health Status And Asthma Control In Patients With Severe Eosinophilic Asthma
    Chupp, G.
    Albers, F. C.
    Nelsen, L. M.
    Bratton, D. J.
    Wang-Jairaj, J.
    Bradford, E.
    Jones, P. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [37] CLINICAL RESPONSE TO MEPOLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA
    Harvey, E.
    Langton, D.
    Powell, H.
    Gibson, P.
    RESPIROLOGY, 2019, 24 : 42 - 42
  • [38] Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients
    Thomas, Dennis
    McDonald, Vanessa M.
    Stevens, Sean
    Harvey, Erin S.
    Baraket, Melissa
    Bardin, Philip
    Bowden, Jeffrey J.
    Bowler, Simon
    Chien, Jimmy
    Chung, Li Ping
    Gillman, Andrew
    Hew, Mark
    Hodge, Sandra
    James, Alan
    Jenkins, Christine
    Katelaris, Constance H.
    Katsoulotos, Gregory P.
    Langton, David
    Lee, Joy
    Marks, Guy
    Peters, Matthew
    Radhakrishna, Naghmeh
    Reynolds, Paul N.
    Rimmer, Janet
    Sivakumaran, Pathmanathan
    Upham, John W.
    Wark, Peter
    Yang, Ian A.
    Gibson, Peter G.
    ALLERGY, 2024, 79 (02) : 384 - 392
  • [39] Clinical response to mepolizumab in patients with severe eosinophilic asthma
    Harvey, Erin
    Langton, David L.
    Powell, Heather
    Gibson, Peter G.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [40] Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis
    Crimi, Claudia
    Campisi, Raffaele
    Cacopardo, Giulia
    Doria, Giacomo
    Intravaia, Rossella
    Morena, Porto
    Sabrina, Genco
    Sorrentino, Ramona
    Crimi, Nunzio
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
12345